Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/97424
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma |
Author: | Hutson, T. Escudier, B. Esteban, E. Bjarnason, G. Lim, H. Pittman, K. Senico, P. Niethammer, A. Lu, D. Hariharan, S. Motzer, R. |
Citation: | Journal of Clinical Oncology, 2014; 32(8):760-767 |
Publisher: | American Society of Clinical Oncology |
Issue Date: | 2014 |
ISSN: | 0732-183X 1527-7755 |
Statement of Responsibility: | Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, Kenneth B. Pittman, Peggy Senico, Andreas Niethammer, Dongrui Ray Lu, Subramanian Hariharan, and Robert J. Motzer |
Abstract: | Abstract not available |
Keywords: | Humans |
Description: | Published online before print December 2, 2013 |
Rights: | © 2013 by American Society of Clinical Oncology |
DOI: | 10.1200/JCO.2013.50.3961 |
Published version: | http://dx.doi.org/10.1200/jco.2013.50.3961 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.